Research/art/teacher profile of a person
Name and surname:
PharmDr. Andrej Kováč, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Kováč
I.2 - Name
Andrej
I.3 - Degrees
PharmDr., Ph.D.
I.4 - Year of birth
1979
I.5 - Name of the workplace
Department of Galenic Pharmacy, Faculty of Pharmacy, Comenius University
I.6 - Address of the workplace
Odbojárov 10, 83232, Bratislava
I.7 - Position
assistant professor
I.8 - E-mail address
kovac133@uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/51763?mode=full
I.10 - Name of the study field in which a person works at the university
Pharmacy
I.11 - ORCID iD
0000-0002-3223-8705

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Faculty of Pharmacy, Comenius University
II.b - Year
2004
II.c - Study field and programme
Pharmacy
II.3 - Third degree of higher education
II.a - Name of the university or institution
Faculty of Medicine Comenius University Bratislava
II.b - Year
2009
II.c - Study field and programme
Immunology
II.4 - Associate professor
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
PI Institute of Neuroimmunology of the Slovak Academy of Sciences 2004-present
post-doc Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, USA 2010-2011
assistant professor The University of Veterinary Medicine and Pharmacy in Košice 2023-present
assistant professor Faculty of Pharmacy, Comenius University 2024-present

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Galenic Pharmacy Pharmacy master study Pharmacy
Pharmacology Pharmacy master study Pharmacy
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.c - Dissertation (third degree)
2
V.4.2 - Number of defended theses
V.4.b - Diploma (second degree)
7
V.4.c - Dissertation (third degree)
5
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Analytical monitoring of drug levels in practice Pharmacy master study Pharmacy

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
152
VI.1.b - Over the last six years
106
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
83
VI.1.b - Over the last six years
56
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
1959
VI.1.b - Over the last six years
1581
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
1959
VI.1.b - Over the last six years
56
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
10
VI.1.b - Over the last six years
8
VI.2 - The most significant research/artistic/other outputs
1

Olešová D, Dobešová D, Majerová P, Brumarová R, Kvasnička A, Kouřil Š, Stevens E, Hanes J, Fialová Ľ, Michalicová A, Piešťanský J, Šinský J, Kaňovský P, Friedecký D, Kováč A. Changes in lipid metabolism track with the progression of neurofibrillary pathology in tauopathies. J Neuroinflammation. 2024 Mar 27;21(1):78. doi: 10.1186/s12974-024-03060-4. PMID: 38539208; PMCID: PMC10976809.

2

Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, Boonkamp L, Novak M, Zetterberg H, Hansson O, Scheltens P, Blennow K, Teunissen CE, Zilka N. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. 2020 Dec 1;95(22):e3026-e3035. doi: 10.1212/WNL.0000000000010814. Epub 2020 Sep 24. PMID: 32973122; PMCID: PMC7734919

3

Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks WA, Zhang J. CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimers Dement. 2016 Nov;12(11):1125-1131. doi: 10.1016/j.jalz.2016.04.003. Epub 2016 May 24. PMID: 27234211; PMCID: PMC5107127.

4

Kovac A, Erickson MA, Banks WA. Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide. J Neuroinflammation. 2011 Oct 13;8:139. doi: 10.1186/1742-2094-8-139. PMID: 21995440; PMCID: PMC3207972.

5

Karlíková R, Mičová K, Najdekr L, Gardlo A, Adam T, Majerová P, Friedecký D, Kováč A. Metabolic status of CSF distinguishes rats with tauopathy from controls. Alzheimers Res Ther. 2017 Sep 21;9(1):78. doi: 10.1186/s13195-017-0303-5. PMID: 28934963; PMCID: PMC5609022.

6

Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging. 2021 Jun;1(6):521-534. doi: 10.1038/s43587-021-00070-2. Epub 2021 Jun 14. PMID: 37117834.

7

Kováč A, Majerová P, Nytka M, Cechová MZ, Bednář P, Hájek R, Cooper-Shepherd DA, Muck A, Lemr K. Separation of Isomeric Tau Phosphopeptides from Alzheimer's Disease Brain by Cyclic Ion Mobility Mass Spectrometry. J Am Soc Mass Spectrom. 2023 Mar 1;34(3):394-400. doi: 10.1021/jasms.2c00289. Epub 2023 Jan 27. PMID: 36706338; PMCID: PMC10017020

8

Kovacech B, Fialova L, Filipcik P, Skrabana R, Zilkova M, Paulenka-Ivanovova N, Kovac A, Palova D, Rolkova GP, Tomkova K, Csokova NT, Markova K, Skrabanova M, Sinska K, Basheer N, Majerova P, Hanes J, Parrak V, Prcina M, Cehlar O, Cente M, Piestansky J, Fresser M, Novak M, Slavikova M, Borsova K, Cabanova V, Brejova B, Vinař T, Nosek J, Klempa B, Eyer L, Hönig V, Palus M, Ruzek D, Vyhlidalova T, Strakova P, Mrazkova B, Zudova D, Koubkova G, Novosadova V, Prochazka J, Sedlacek R, Zilka N, Kontsekova E. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine. 2022 Feb;76:103818. doi: 10.1016/j.ebiom.2022.103818. Epub 2022 Jan 22. PMID: 35078012; PMCID: PMC8782626.

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Olešová D, Dobešová D, Majerová P, Brumarová R, Kvasnička A, Kouřil Š, Stevens E, Hanes J, Fialová Ľ, Michalicová A, Piešťanský J, Šinský J, Kaňovský P, Friedecký D, Kováč A. Changes in lipid metabolism track with the progression of neurofibrillary pathology in tauopathies. J Neuroinflammation. 2024 Mar 27;21(1):78. doi: 10.1186/s12974-024-03060-4. PMID: 38539208; PMCID: PMC10976809.

2

Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging. 2021 Jun;1(6):521-534. doi: 10.1038/s43587-021-00070-2. Epub 2021 Jun 14. PMID: 37117834.

3

Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, Boonkamp L, Novak M, Zetterberg H, Hansson O, Scheltens P, Blennow K, Teunissen CE, Zilka N. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. 2020 Dec 1;95(22):e3026-e3035. doi: 10.1212/WNL.0000000000010814. Epub 2020 Sep 24. PMID: 32973122; PMCID: PMC7734919

4

Kovacech B, Fialova L, Filipcik P, Skrabana R, Zilkova M, Paulenka-Ivanovova N, Kovac A, Palova D, Rolkova GP, Tomkova K, Csokova NT, Markova K, Skrabanova M, Sinska K, Basheer N, Majerova P, Hanes J, Parrak V, Prcina M, Cehlar O, Cente M, Piestansky J, Fresser M, Novak M, Slavikova M, Borsova K, Cabanova V, Brejova B, Vinař T, Nosek J, Klempa B, Eyer L, Hönig V, Palus M, Ruzek D, Vyhlidalova T, Strakova P, Mrazkova B, Zudova D, Koubkova G, Novosadova V, Prochazka J, Sedlacek R, Zilka N, Kontsekova E. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine. 2022 Feb;76:103818. doi: 10.1016/j.ebiom.2022.103818. Epub 2022 Jan 22. PMID: 35078012; PMCID: PMC8782626.

5

Majerova P, Michalicova A, Cente M, Hanes J, Vegh J, Kittel A, Kosikova N, Cigankova V, Mihaljevic S, Jadhav S, Kovac A. Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies. PLoS One. 2019 May 23;14(5)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Lai R, Li B, Bishnoi R. P-tau217 as a Reliable Blood-Based Marker of Alzheimer's Disease. Biomedicines. 2024 Aug 13;12(8):1836. doi: 10.3390/biomedicines12081836. PMID: 39200300; PMCID: PMC11351463.

2

Kawarabayashi T, Nakamura T, Miyashita K, Segawa T, Fukamachi I, Sugawara T, Oka H, Ishizawa K, Amari M, Kasahara H, Makioka K, Ikeda Y, Takatama M, Shoji M. Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases. J Alzheimers Dis. 2023;96(4):1623-1638. doi: 10.3233/JAD-230419. PMID: 38007650; PMCID: PMC10741340.

3

Wang Q, Chen S, Wang J, Shang H, Chen X. Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sci. 2024 Sep 29;14(10):990. doi: 10.3390/brainsci14100990. PMID: 39452004; PMCID: PMC11506318.

4

Zhu K, Pieber M, Han J, Blomgren K, Zhang XM, Harris RA, Lund H. Absence of microglia or presence of peripherally-derived macrophages does not affect tau pathology in young or old hTau mice. Glia. 2020 Jul;68(7):1466-1478. doi: 10.1002/glia.23794. Epub 2020 Feb 10. PMID: 32039516.

5

Duan J, Lv A, Guo Z, Liu Q, Tian C, Yang Y, Bi J, Yu X, Peng G, Luo B, Cai Z, Xu B, Fu Y, Zhang J. CX3CR1+/UCHL1+ microglial extracellular vesicles in blood: a potential biomarker for multiple sclerosis. J Neuroinflammation. 2024 Oct 9;21(1):254. doi: 10.1186/s12974-024-03243-z. PMID: 39385200; PMCID: PMC11465848.

6

Stroganova I, Willenberg H, Tente T, Depraz Depland A, Bakels S, Rijs AM. Exploring the Aggregation Propensity of PHF6 Peptide Segments of the Tau Protein Using Ion Mobility Mass Spectrometry Techniques. Anal Chem. 2024 Apr 2;96(13):5115-5124. doi: 10.1021/acs.analchem.3c04974. Epub 2024 Mar 22. PMID: 38517679; PMCID: PMC10993201.

7

Wu YC, Bogale TA, Koistinaho J, Pizzi M, Rolova T, Bellucci A. The contribution of β-amyloid, Tau and α-synuclein to blood-brain barrier damage in neurodegenerative disorders. Acta Neuropathol. 2024 Feb 12;147(1):39. doi: 10.1007/s00401-024-02696-z. PMID: 38347288; PMCID: PMC10861401.

8

Bryant AG, Hu M, Carlyle BC, Arnold SE, Frosch MP, Das S, Hyman BT, Bennett RE. Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. Front Neurol. 2020 Sep 16;11:575953. doi: 10.3389/fneur.2020.575953. PMID: 33041998; PMCID: PMC7525127.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

APVV-21-0321 - Mechanism of tau protein movement through and out of the brain (principal investigator).

2

VEGA 2/0078/22 - Novel receptor-mediated delivery system for brain therapeutics(principal investigator).

3

VEGA 2/0150/19 - Link between Tauopathies and Diabetes and Modulation of their Pathology by PACAP as Neuroprotective Peptide (principal investigator).

4

APVV-18-0302 - The development of novel approaches for pre-clinical diagnostics and therapy for tauopathies using transport peptides for drugs and antibodies into the brain (principal investigator).

5

ICGEB - The tryptophan kynurenine pathway- therapeutic strategy for neuroprotection in tauopathies (Principal investigator).

6

2018/24-SAV-2 - Development of new neuroimaging approaches for therapy and preclinical diagnosis of tauopathies using transport peptides for tau specific nanobodies to the brain (principal investigator).

7

APVV-22-0313 - Novel Insights into Tauopathy Mechanism: Lipids as a Tool to Control Neurodegeneration and Neuroinflammation (principal investigator).

8

09I03-03-V03-00086 - Translational research for diagnosis and treatment of heatstroke (principal investigator).

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Division of Gerontology and Geriatric Medicine, University of Washington Seattle, USA 1.12.2010-1.12.2011 post-doc
Division of Gerontology and Geriatric Medicine, University of Washington Seattle, USA 15.7.2022-31.10.2022 Fulbright Slovak Scholar Program

IX. - Other relevant facts

Date of last update
2024-11-08